Kornimate/medical-research-clean huggingface dataset:
effect of photodynamic therapy on gingival crevicular cytokines in periodontitis patients

Conditions: Periodontitis, Adult; Periodontal Pocket; Periodontitis; Periodontal Attachment Loss

Summary: systemically healthy periodontitis patients were recruited in this single-blind, split-mouth, randomized controlled clinical trial. after srp, pdt was applied at probing depth (pd) ≥ 4 mm at test quadrant. at baseline, 3rd month and 6th month, clinical parameters and cytokine pattern in gingival crevicular fluids (gcfs) were analysed.

periodontal parameters and cytokine il-1β, il-6, il-8, tnf-α, mmp-8 levels were analysed.

Eligibility criteria:
inclusion criteria: * adults who were medically fit or have medical condition that did not alter the outcome of periodontal treatment. * females who were not pregnant or nursing. * controlled diabetes mellitus with hba1c \< 7.5 mmol/l. * not on any antibiotics or steroids 3 months prior to periodontal treatment. * diagnosed to have either localized or generalized chronic or aggressive periodontitis (armitage, 1999) with all 4 quadrants having at least 2 sites with probing depth ≥ 4 mm. * consented to follow the non-surgical periodontal treatment (scaling and root planing) with pdt throughout the period of study, i.e. approximately 6 months. exclusion criteria: * allergic to photosensitizer or dye * pregnant lady and nursing mothers * uncontrolled diabetes

Keywords: photodynamic therapy interleukin 1-beta tumour necrosis factor - alpha interleukin-6 interleukin-8 matrix metalloproteinase-8
empathy levels among undergraduate medical students in karachi, pakistan - a cross-sectional study

Conditions: Empathy

Summary: empathy is a concept native to the field of medicine. however, over the course of medical school, empathy levels are expected to decline. the aim of this study was to assess the empathy levels amongst medical students in relation to their year of study and specialties of choice in the future. a cross-sectional study was conducted to assess empathy levels among students from medical colleges in karachi, pakistan, using an online survey. the total duration of the study was two months. the authors analyzed the data using spss version 20. a total of 463 undergraduate medical students participated in this survey.


Eligibility criteria:
inclusion criteria: * undergraduate medical students exclusion criteria: * all the remaining population

Keywords: empathy medical students pakistan surveys and questionnaires observational study
efficacy research of bimanual intensive training in children with hemiplegic cerebral palsy

Conditions: Cerebral Palsy

Summary: this research project aims to investigate the feasibility, efficacy, and acceptability of camp-based model of bit.


Eligibility criteria:
inclusion criteria: 1. diagnosis of cerebral palsy(cp) with one or more affected sides. 2. considerable nonuse of the affected upper limb (amount-of-use score of the pediatric motor activity log \< 2.5). 3. no excessive muscle tone (modified ashworth scale ≤ 2 at any joints of the upper limb) before beginning treatment. 4. no severe cognitive, visual, or auditory disorders according to medical documents, parental reports, and the examiner 's clinical observation. 5. no injections of botulinum toxin type a or operations on the upper limb within 6 months.

Keywords: cerebral palsy, bimanual intensive training, occupational therapy
prophylactic modified mccall culdoplasty during total laparoscopic hysterectomy

Conditions: Vaginal Vault Prolapse; Sexual Function

Summary: the purpose of this study is to assess the feasibility of performing prophylactic mccall culdoplasty at the time of total laparoscopic hysterectomy. the investigators will also be measuring pelvic support (using pop-q) and sexual function before and at different time points (up to 12 months) postoperatively. the investigators hypothesize that women undergoing the mccall culdoplasty will not have different immediate surgical outcomes (operative time, etc) and may have better pelvic support and sexual function in the future.


Eligibility criteria:
inclusion criteria: * women aged 18-99 undergoing elective laparoscopic hysterectomy for benign indications with surgeons in the division of advanced laparoscopy and pelvic pain at unc-chapel hill. exclusion criteria: * current symptomatic or asymptomatic pelvic organ prolapse as measured by the pelvic organ prolapse quantification (popq) system. * pregnancy * non-english speaking * unable to provide informed consent * pathology causing an obliterated cul-de-sac

Keywords: mccall culdoplasty total laparoscopic hysterectomy vaginal vault prolapse sexual function
hanover humerus registry

Conditions: Proximal Humerus Fracture

Summary: this register study collects data of patients with proximal humerus and humerus shaft fractures to monitor the healing process by assessing shoulder function and quality of life according to the treatment method (operative or conservative management).

this prospective data collection of patients with proximal humerus and humerus shaft fractures in a lifelong aftercare treatment plan is for analyzing the healing process in one patient and compared in the whole cohort. according to actual scientific and clinical issues can this data collection be a basis in optimizing the treatment method.

Eligibility criteria:
inclusion criteria: * patients with trauma-related proximal humerus and humerus shaft fracture * cognitively able to fill out a questionaire * signed informed consent exclusion criteria: * patients with oncological-related proximal humerus and humerus shaft fracture * cognitively not able to fill out a questionaire * no informed consent

Keywords: shoulder fractures humeral fractures operative therapy conservative therapy range of motion, articular quality of life proximal
dose reduction of il17 and il23 inhibitors in psoriasis

Conditions: Psoriasis; Psoriasis Vulgaris

Summary: the main objective of this study is to investigate whether controlled dose reduction of il17 or il23 inhibiting biologics is not inferior compared to usual care in psoriasis patients. therefore, a pragmatic, multicentre, randomized, controlled, non-inferiority study will be carried out.

rationale: biologics are very effective treatments for psoriasis. research indicated that the dose of tnfα-blocking biologics can be reduced in a proportion of patients. safety profiles can improve and costs can be reduced if the reduction of the dose is successful. recently, the newest generation of biologics entered the market: interleukin (il) 17 and il23 inhibitors. it is not yet known whether dose reduction of these agents is possible, and to what extent they can be reduced. the timely investigation of the possibilities for dose reduction of new biologics is therefore important. objectives: the primary goal is to investigate whether controlled dose reduction of il17 or il23 inhibiting biologics is not inferior compared to usual care. this is measured by comparing the proportion of long-term disease flares between the two groups (dose reduction group versus usual care group). secondary goals are: determining the proportion of patients with successful dose reduction, clinical effectiveness measured with the psoriasis area and severity score (pasi) score, dermatology life quality index (dlqi) scores, predictors for successful dose reduction, safety, and cost-effectiveness of dose reduction. pharmacokinetic (pk) analysis will be performed for modeling. study design: a multicenter, practice-oriented, pragmatic, randomized, controlled, non-inferiority study. study population: patients treated with the newest generation of biologics (il17 or il23 inhibitors), with long-term stable low disease activity at a normal dose. a total of 244 patients will be randomized (2:1) to dose reduction or continuation of usual care. intervention: dose reduction by interval prolongation in 2 steps to a maximum decrease of 50% of the original dose when disease activity (pasi) and quality of life index (dlqi) remain low.

Eligibility criteria:
inclusion criteria: * plaque psoriasis (primarily) * treatment for at least 6 months with il23 or il17 inhibitor in a normal dose (dose advised by the label) * pasi≤ 5 at inclusion and in previous 6 months (if no pasi scores are available, it should be clear from the patient record that psoriasis was clear/almost clear in previous 6 months). * dlqi ≤ 5 at inclusion exclusion criteria: * another indication than plaque psoriasis as the main indication for biologic use (e.g. patient receives biologic for rheumatoid arthritis as the main indication). * concomitant use of systemic immunosuppressants other than methotrexate or acitretin (e.g. prednisone, cyclosporine etc). * severe comorbidities with short life-expectancy (e.g. metastasized tumor). * presumed inability to follow the study protocol.

Keywords: skin diseases skin diseases (papulosquamous) biologicals il17 inhibitors il23 inhibitors dose reduction
the impact of low pressure pneumo in rarp ii

Conditions: Prostate Cancer

Summary: the purpose of this study is to evaluate clinical significance of low pressure pneumoperitoneum during robotically assisted radical prostatectomy (rarp).

laparoscopic and robotic surgery has revolutionized post-operative outcomes across surgical specialties. however, the use of pneumoperitoneum comes with known risks given the change in physiological parameters that accompany its utilization. the effects of increased intra-abdominal pressure on cardiopulmonary function has been well documented. increased pressure on the large vessels may lead to decreased cardiac output and thereby decreased blood flow to various organ systems and cause irreversible damage. some studies have advocated lower pressures to further optimize cardiopulmonary parameters. mcdougall, et. al, for instance, demonstrated a significant reduction in oliguria when pressures of 10mm hg were used. the purpose of this study is to evaluate the effect of using lower pressure pneumoperitoneum in the abdominal cavity during rarp. the investigators hypothesize that low pressure pneumoperitoneum has a multitude of clinical benefits due to improved physiologic parameters including a reduction in the occurrence of post-operative ileus, reduced need for narcotics post operatively, and a decrease in cardiopulmonary complications. a previously completed study concluded a reduction in post-operative ileus at a pneumoperitoneum pressure of 8 mm hg vs 12 mm hg. this new study will evaluate the standard pneumoperitoneum pressure of 15 mm hg vs 12 mm hg in order to validate the previous study vs the standard pneumoperitoneum pressure. the study is a prospective randomized blinded cohort study. patients who meet eligibility criteria will be randomly assigned to undergo rarp at a pneumoperitoneum pressure of 15mm hg or 12mm hg. this will be done by computer generated randomization protocol. surgeon and patients will be blinded to the pneumoperitoneum pressure used. a cover will be placed over the insufflation system so that the surgeon(s) are not able to visualize the pneumoperitoneum used during the procedure. the remainder of the procedure will be carried out based on current standard of care. all patients will be admitted post operatively and the same standardized orderset in epic ehr will be used for all patients in order to control for other factors, such as opioid use, to control for confounders.

Eligibility criteria:
inclusion criteria: - male 40 years of age or older * diagnosis of prostate cancer * have been evaluated to be fit for proposed surgery * patients able to consent exclusion criteria: - patients unable to consent (cognitively impaired) • non-english speaking

Keywords: radical prostatectomy robotic assisted radical prostatectomy
to measure pain perception following de-epithelized free gingival graft harvesting

Conditions: Gingival Recession; Palate; Wound

Summary: this randomized clinical comparative study will evaluate the postoperative pain following the fgg graft harvest procedure technique covered by four different methods for coverage of the palatal donor site.

this study will compare the application of : * hemostatic collagen sponge * collagen sponge sealed with abio-adhesive material * platelet rich fibrin * physical barrier (stent) on the palatal donor sites with the purpose of which one of these will result in least postoperative pain after epithelialized gingival graft (egg) harvesting.

Eligibility criteria:
inclusion criteria: * english speaking * at least 18 years old- 70 years old * must be a patient of the uab dental school * able to read and understand informed consent document * patients needing soft tissue graft with teeth that have miller class i or ii recession (\>=2mm) on the facial aspects * presence of periodontally healthy teeth at the recipient site. * ability of the participants to maintain good oral hygiene * patient not pregnant or breastfeeding * not taking medications known to cause gingival enlargement exclusion criteria: * non-english speaking * less than 18 years old, older than 70 years old * smokers/tobacco users * patients with systemic pathologies or conditions contraindicating oral surgical procedures or adversely affecting wound healing * patients that have severe gingival recession (miller class iii and iv) or \< 2 mm. * presence of periodontal disease at the recipient site. * poor oral hygiene * patient pregnant or breastfeeding * taking medications known to cause gingival enlargement
hellenic registry for ciais (herco-ii)

Conditions: Intra-abdominal Infection

Summary: complicated intra-abdominal infections (ciais) represent an emergent surgical situation which lead to important non trauma-related mortality in several emergency surgical centers worldwide. their prevalence seemed to be unrelated to age, gender, health status and socioeconomic condition. early diagnosis, timely septic source control, wide-spectrum antibiotic delivery and resuscitation with fluids and vasoactive agents in critically ill patients are fundamentals for successful ciais management. moreover, septic shock, antibiotic resistant multi-pathogens and comorbidities have been associated with increased morbidity and mortality of ciais. several international health associations announce updated guidelines for ciais management. nevertheless, such guidelines could not be widely implemented, because of specific features of several healthcare systems worldwide. the aim of the present study is to investigate the prevalence of ciais among the greek health system and the potential association of time interval of septic source control, preoperative resuscitation and multidrug resistant pathogens with morbidity, mortality, icu stay and length of stay in patients with ciais.

registry of patients with complicated intra-abdominal infections including: * patient demographics (gender, age, carlson comorbidity index, cancer history/chemotherapy during the last 6 months, health unit stay during the last 6 months) * management (conservative, minimally invasive, surgical) * minimally invasive procedure - type (ct-guided drainage, endoscopic) * surgical procedure - type (open or laparoscopic, day or night, procedure description) * cultures (blood, peritoneal fluid, tissue) * time of diagnosis (respiratory rate, heart rate, systolic blood pressure, lactate acid in blood gases, temperature, white cell count, crp) * just before procedure (respiratory rate, heart rate, systolic blood pressure, lactate acid in blood gases, vasoactive agent delivery, intubation) * intraoperative parameters (time interval between diagnosis and intervention, wses score, operative time, open abdomen, vac) * after procedure (respiratory rate, heart rate, systolic blood pressure, lactate acid in blood gases, temperature, vasoactive agent delivery, intubation) * empirical wide-spectrum antibiotics (type and time interval from diagnosis)

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old 2. signed consent from patient or authorized representative 3. complicated intra-abdominal infection * acute appendicitis with localized or diffuse peritonitis * grade ii or grade iii acute cholecystitis (tokyo guidelines) * visceral organ perforation with peritonitis * bowel perforation after colonoscopy * complicated diverticulitis (wses classification) * anastomotic leaks with abscess, localized or diffuse peritonitis exclusion criteria: 1. age \< 18 years old 2. no signed consent from patient or authorized representative

Keywords: complicated intra-abdominal infection greek
a phase iii trial of hrs-1893 in patients with obstructive hypertrophic cardiomyopathy

Conditions: Obstructive Hypertrophic Cardiomyopathy

Summary: the study is being conducted to evaluate the efficacy and safety of hrs-1893 for obstructive hypertrophic cardiomyopathy.


Eligibility criteria:
inclusion criteria: 1. age 18-85 years old, gender unlimited. 2. bmi\<35 kg/m2. 3. the diagnosis was obstructive hypertrophic cardiomyopathy. 4. laboratory determination of echocardiography showed that rest lvot-g≥50 mmhg, or rest lvot-g≥30 mmhg and lvot-g≥50 mmhg after valsalva action. 5. echocardiographic laboratory tests showed lvef≥60%. 6. nyha classification: grade ii - iii. 7. understand the study procedure and sign the informed consent in person, willing to strictly follow the clinical study protocol to complete the study. exclusion criteria: 1. known or suspected invasive, genetic or storage diseases (e.g. noonan syndrome, fabre's disease, amyloidosis) that cause cardiac hypertrophy (similar to ohcm). 2. had a history of severe valvular heart disease. 3. abnormal laboratory test results during screening, or any other clinically significant abnormal screening laboratory values, which are determined by the researcher to be unsuitable for inclusion. 4. other circumstances where the researchers consider the subjects unsuitable to participate in this trial, such as physical or mental illnesses or conditions that may increase the risk of the trial, affect the subjects' compliance with the protocol, or affect the subjects' completion of the trial.
safety and efficacy study of eculizumab in patients with mild allergic asthma

Conditions: Allergic Asthma

Summary: this study is to designed to test the role of complement in the late asthmatic response to allergen challenge in mild asthma, as an indicator of the possible role of complement in the broader asthmatic population.


Eligibility criteria:
inclusion criteria: * diagnosed with stable, mild, allergic asthma; * history of episodic wheeze and shortness of breath; * sexually active women of childbearing potential must use contraceptive during the entire duration of study; * willing and able to give informed consent; * positive methacholine challenge; * positive skin prick test to common aeroallergens; * positive allergen-induced early and late phase bronchoconstrictor response * fev1 at least 70% of predicted value; * pc20 at baseline that is within 1 doubling dose of that measured during screening exclusion: * active bacterial infection; * respiratory tract infection or worsening of asthma within 28 days * use of inhaled or topical steroids within 28 days or use of systemic corticosteroids within 90 days; * use of cromoglycate, nedocromil, leukotriene receptor antagonists and inhibitors of 5-lipoxygenase within 14 days; * use of antihistamines, immunosuppressives, or any medications that interact with eculizumab; * use of theophylline-containing agents (any type), long-acting beta 2-agonists (salmeterol, formoterol) or long-acting anticholinergics within 14 days; * use of nsaids prior to spirometry; * use of tobacco products currently or within the previous 12 months; or smoking history \> 10 pack-years; * lung disease other than mild allergic asthma; * patients with lar who have not been vaccinated against neisseria meningitidis; * hepatitis b or hiv infection; * parasitic infection; * participation in any other investigational drug trial; * pregnant or breast feeding women, or intending to conceive during the course of trial; * known hypersensitivity to the treatment drug or any of its excipients; * history of illicit drug use or alcohol abuse within previous year; * any clinically significant abnormality on screening lab test results; * abnormal chest x-ray; * chronic use of any other medication for treatment of allergic lung disease other than short-acting beta2-agonists or ipratropium bromide; * any medical condition that might interfere with the subject's participation in the study or confound the assessment of the subject; * unwilling or inability to comply with the study protocol for any reason.
product surveillance registry

Conditions: Cardiac Rhythm Disorders; Urological Disorders; Neurological Disorders; Cardiovascular Disorders; Digestive Disorders; Intracranial Aneurysm; Mechanical Circulatory Support; Respiratory Therapy; Aortic, Peripheral Vascular and Venous Disorders; Minimally Invasive Surgical Procedures; Diagnostic Techniques and Procedures; Surgical Procedures, Operative; Renal Insufficiency; Neurovascular; Coronary Artery Disease; Ear, Nose and Throat Disorder

Summary: the purpose of the registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of medtronic market-released products. the registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge performance assessment via the least burdensome approach.


Eligibility criteria:
inclusion criteria: * patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements * patient has or is intended to receive or be treated with an eligible medtronic product * patient within enrollment window relative to therapy initiation or meets criteria for retrospective enrollment exclusion criteria: * patient who is, or will be, inaccessible for follow-up * patient with exclusion criteria required by local law * patient is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound results